Pediatrix Medical Group Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Pediatrix Medical Group de 47.5% y 3.3% por año respectivamente. Se prevé que el BPA crezca en un 48.3% al año. Se espera que la rentabilidad financiera sea de 10.5% en 3 años.

Información clave

53.2%

Tasa de crecimiento de los beneficios

54.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	17.3%
Tasa de crecimiento de los ingresos	2.2%
Rentabilidad financiera futura	11.5%
Cobertura de analistas	Good
Última actualización	07 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger

May 10

Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking

Mar 29

Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 10

Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Dec 25

Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold

Aug 08

At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

Jul 03

The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Jun 08

Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Apr 26

Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Feb 20

Pediatrix Medical Group Q4 2022 Earnings Preview

Feb 16

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Jan 12

Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold

Dec 22

Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Dec 20

Pediatrix appoints James Swift as chief executive officer

Dec 15

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Nov 05

Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M

Nov 03

Pediatrix: These 5 Graphs Suggest It's A Buy

Sep 29

Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly

Sep 13

Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return

Aug 29

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Jul 27

Pediatrix: Seeking 46% Return Objective As Speculative Buy

Jul 14

MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jun 24

MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet

May 25

Return Trends At MEDNAX (NYSE:MD) Aren't Appealing

Apr 20

MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 08

MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly

Feb 15

Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

Jan 19

Is MEDNAX, Inc. (NYSE:MD) Trading At A 40% Discount?

Nov 17

These 4 Measures Indicate That MEDNAX (NYSE:MD) Is Using Debt Reasonably Well

Oct 23

Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

Oct 08

Is MEDNAX (NYSE:MD) A Risky Investment?

Jul 19

MEDNAX (NYSE:MD) Could Be Struggling To Allocate Capital

Jun 27

Statutory Profit Doesn't Reflect How Good MEDNAX's (NYSE:MD) Earnings Are

May 15

Mednax Q1 2021 Earnings Preview

May 06

Does MEDNAX (NYSE:MD) Have A Healthy Balance Sheet?

Mar 14

Previsiones de crecimiento de beneficios e ingresos

NYSE:MD - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2,136	71	N/A	N/A	3
12/31/2025	2,059	89	108	143	7
12/31/2024	2,017	75	103	137	7
3/31/2024	1,999	-71	81	113	N/A
12/31/2023	1,995	-60	104	137	N/A
9/30/2023	2,012	88	133	167	N/A
6/30/2023	1,995	95	139	170	N/A
3/31/2023	1,981	98	134	164	N/A
12/31/2022	1,972	63	137	167	N/A
9/30/2022	1,957	79	89	112	N/A
6/30/2022	1,960	82	63	90	N/A
3/31/2022	1,947	82	31	61	N/A
12/31/2021	1,911	108	44	77	N/A
9/30/2021	1,829	72	-15	21	N/A
6/30/2021	1,797	38	99	129	N/A
3/31/2021	1,739	14	236	264	N/A
12/31/2020	1,734	-10	176	205	N/A
9/30/2020	1,776	-4	326	352	N/A
6/30/2020	1,770	11	321	341	N/A
3/31/2020	1,678	1	261	284	N/A
12/31/2019	1,780	42	338	358	N/A
9/30/2019	2,210	94	331	351	N/A
6/30/2019	2,603	143	292	320	N/A
3/31/2019	3,145	221	296	324	N/A
12/31/2018	1,723	122	297	314	N/A
9/30/2018	3,477	333	303	346	N/A
6/30/2018	3,497	337	371	417	N/A
3/31/2018	3,475	326	373	420	N/A
12/31/2017	3,253	305	N/A	498	N/A
9/30/2017	3,378	262	N/A	447	N/A
6/30/2017	3,337	293	N/A	443	N/A
3/31/2017	3,266	312	N/A	455	N/A
12/31/2016	3,183	325	N/A	444	N/A
9/30/2016	3,094	340	N/A	417	N/A
6/30/2016	2,988	334	N/A	393	N/A
3/31/2016	2,893	336	N/A	389	N/A
12/31/2015	2,780	336	N/A	369	N/A
9/30/2015	2,689	332	N/A	443	N/A
6/30/2015	2,593	327	N/A	431	N/A
3/31/2015	2,512	322	N/A	419	N/A
12/31/2014	2,439	317	N/A	423	N/A
9/30/2014	2,356	308	N/A	383	N/A
6/30/2014	2,284	299	N/A	382	N/A
3/31/2014	2,218	289	N/A	374	N/A
12/31/2013	2,154	281	N/A	405	N/A
9/30/2013	2,058	268	N/A	371	N/A
6/30/2013	1,976	257	N/A	348	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MD sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que MD sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que MD sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (3.3% al año) de MD crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 3.3% al año) de MD crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de MD sea baja dentro de 3 años (10.5%).

Pediatrix Medical Group Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 8.0% to US$9.07

Consensus EPS estimates fall by 21%

Price target decreased by 12% to US$14.80

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 17%

Price target decreased to US$22.33

Recent updates

Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger

New major risk - Financial position

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Pediatrix Medical Group, Inc. to Report Q1, 2024 Results on May 07, 2024

Pediatrix Medical Group, Inc., Annual General Meeting, May 09, 2024

Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking

Price target decreased by 8.0% to US$9.07

Full year 2023 earnings: EPS and revenues miss analyst expectations

Pediatrix Medical Group, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Consensus EPS estimates fall by 21%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS misses analyst expectations

Pediatrix Medical Group, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?

Price target decreased by 12% to US$14.80

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold

Second quarter 2023 earnings: EPS misses analyst expectations

At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

CEO & Director recently sold US$187k worth of stock

The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Independent Director recently sold US$258k worth of stock

Pediatrix Medical Group, Inc. Appoints Sylvia Young as an Independent Director, Effective May 12, 2023

First quarter 2023 earnings: EPS misses analyst expectations

Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Consensus EPS estimates fall by 11%

Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Full year 2022 earnings: EPS misses analyst expectations

Pediatrix Medical Group Q4 2022 Earnings Preview

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold

Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Pediatrix Medical Group, Inc. Announces Executive Changes

Pediatrix appoints James Swift as chief executive officer

CEO & Director recently sold US$342k worth of stock

High number of new and inexperienced directors

Executive VP & Chief Operating Officer recently sold US$367k worth of stock

Consensus EPS estimates fall by 17%

Investor sentiment deteriorated over the past week

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M

Pediatrix Medical Group, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Pediatrix: These 5 Graphs Suggest It's A Buy

Pediatrix Medical Group, Inc. Announces Executive Changes

Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly

Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Pediatrix Medical Group, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Pediatrix: Seeking 46% Return Objective As Speculative Buy

MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate

Price target decreased to US$22.33

MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet

Mednax Announces Leadership Appointments

Consensus forecasts updated

Price target decreased to US$24.89

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

MEDNAX, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Return Trends At MEDNAX (NYSE:MD) Aren't Appealing

MEDNAX, Inc., Annual General Meeting, May 12, 2022

MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price

MEDNAX, Inc. Announces Resignation of Roger Mack Hinson as President of Pediatrix and Obstetrix Medical Group, Effective as of June 1, 2022

Consensus EPS estimates increase by 11%

Full year 2021 earnings: EPS exceeds analyst expectations